KYLEENA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
KYLEENA is a levonorgestrel-releasing intrauterine system (IUS) approved by the FDA in September 2016 for contraception. It is a small-molecule progestin device that provides long-acting reversible contraception by releasing levonorgestrel directly into the uterus. The drug works through local progestin activity to prevent pregnancy.
KYLEENA is in peak lifecycle with stable Part D utilization, indicating a mature commercial organization with moderate-sized field and marketing teams supporting contraceptive franchise growth.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on KYLEENA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
KYLEENA is a peak-stage, mature contraceptive product with limited linked job postings, indicating a stable but not rapidly expanding team. Roles focus on defending market share, managing patient access, and preparing for generic entry beginning 2027.